Abstract Molecular imaging employing 18 [F]FDG-PET/ CT enables in-vivo visualization, characterisation and measurement of biological process in tumour at the molecular and cellular level. In oncology, this approach can be directly applied as translational biomarkers of disease progression. In this article, the improved roles of FDG as an in-vivo glycolytic marker which reflect biological changes across in-vitro cellular environment are discussed. New understanding in how altered metabolism via glycolytic downstream drivers of malignant transformation as reviewed below offers unique promise as to monitor tumour aggressiveness and hence optimize the therapeutic management.
Introduction
Molecular imaging (MI) enables non-invasive monitoring processes at a molecular or genetic level in vivo. In this regard, MI modalities can be exploited in oncology as biomarkers of disease progression. Leveraging the rapidly increasing pace of technological and scientific innovation in molecular biology, there has been a surge in the understanding of the key drivers of malignant transformation. Tumour cells emerge as a result of genetic alteration of signal circuitries promoting cell growth and survival, whereas their expansion relies on nutrient supply. Heterogeneity of malignant cell clones in different sites within a single tumour and between different tumour sites in the body is a manifestation of the genomic instability that characterises cancer cells [1] . These cells frequently express large numbers of cell surface antigens that are present in a minority of normal cells, or that are expressed at much lower concentrations. The role of these overexpressed surface proteins is often unknown.
In-vitro assessment of proliferative rates of tumours has advanced with the development of immunohistochemical techniques tumour biomarkers markers such as Ki-67, Glut-1, p53 which label cells in different states of biological activity (Table 1) . Although various forms of in-vivo imaging techniques, including magnetic resonance imaging MRI, CT, ultrasound etc. are being utilised, they are not highly selective for cancer. Largely independent of structural disturbances, integrated MI, i.e. 18 [F]2-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography/ computed tomography (PET/CT) technique increasingly offers high spatial resolution and high contrast. Disordered metabolism or physiology can be detected with high sensitivity and the anatomical distribution of abnormality can be determined with greater precision than the conventional technique.
In this article, we will mainly revise the utilities of FDG in an integrated PET/CT imaging in primary application for cancer pertaining to its amelioration as a role of biomarker in signaling specific intracellular tumour biology. Update on the utility of this hybrid imaging offers new insight far better than the conventional use of 18 [F]FDG-PET alone which is important in offering a revised valuable information for appropriate treatment in oncology.
Standard Uptake Value (SUV)
Quantitative evaluation of FDG-PET images provides quantitative data in the form of the SUV. This is an uptake measurement that provides a mean of comparison of FDG uptake between different lesions. Measurement of SUV requires attenuation correction to avoid the variability in FDG uptake due to the differences in tumour habitus within the body. This value normalises the tumour FDG uptake with the FDG-injected activity and the body weight [2] . The cut-off value of 2.5 in differentiating malignant to benign is at large limited due to varied tumour histological characteristic in malignant tumour [3] . This is supported by a published data as evaluated in a study on 173 patients with pulmonary nodule which found that the cut-off value of 2.5 is not useful in assessing a large nodule[1.0 cm [4] . In addition, there is an escalating evidence that connote the relationship of SUV values with the degree of tumour aggressiveness which renders further understanding and evidence of the FDG as a biomarker in the evaluation of tumour characters (Table 2) .
FDG as a Ligand to 18 [F] Radionuclide in Tumour Biology One of the primary metabolic changes associated with proliferating tumour cells is induction of aerobic glycolysis. Glucose is a critical nutrient for proliferating cells [5] . It serves as the primary substrate for ATP generation and is an essential of duplication of macromolecules and protein to ensure successful passage through the cell cycle. FDG is an analogue of glucose and is taken up by living cells via the first stages of normal glucose pathway (Fig. 1) . The rationale behind its use as a tracer for cancer diagnosis depends on an increased glycolytic activity in neoplastic cells. In proliferating cells, the majority of the pyruvate generated from glucose ([90 %) is converted to lactate by lactate dehydrogenase (LDH-A), where it is readily secreted into extracellular environment instead of oxidized to completion. In other words, metabolic activities induced by proliferating cells would result in an anabolic shift in cellular metabolism [6] .
In vivo, the glucose analogue-FDG is a ligand used in labelling the tumour targets. The use of Fluorine-18 ( 18 [F] ) as a PET tracer helps to signify the role of this ligand in tumours. This molecular probe can target tumour either through the 'enhanced permeability' and 'retention' effect (EPR effect) of the tumour microvasculatures or by the specific binding between the tumour cell receptors and biomolecules-modified nanoparticles (Fig. 1 ). In vitro, molecular markers, i.e. Glut-1, Ki-67, p53 which are traditionally used to signify tumour aggressiveness, monitoring treatment response and staging, has been shown to have good correlation with SUV in many studies [7, 8] .
FDG Signifies the Oxygen-Limiting Factor in Tumour Cell
A common property of invasive cancers is altered glucose metabolism. Oxygen limitation is central in controlling neovascularization, glucose metabolism, survival and tumour spread. This action is orchestrated by hypoxiainducible factor (HIF), which is a master transcriptional factor in nutrient stress signaling.
In vivo, intense uptake and metabolism of glucose, a frequent characteristic of most cancer cells, is associated with an alteration in the intrinsic energy metabolism causing a shift from oxidative phosphorylation to aerobic glycolysis, a change referred to as the Warburg effect [9] . The phosphorylized FDG compound does not enter in the Krebs cycle, thence it is effectively trapped. Because glycolysis is considerably less efficient than oxidative phosphorylation at producing adenosine triphosphate (ATP), the tumour cell requires acceleration in the rate of glucose uptake and use. [40] How the alteration of the glucose metabolism occurs in cancer requires further understanding of what are the molecular mechanisms that underpin metabolic reprogramming. These mechanisms are complex and involve adaptive responses to the tumour microenvironment such as hypoxia, mutations in enzymes or oncogenes that control cell metabolism [10] . Most of tumours are histologically distinct but clinically heterogeneous entity including multiple anatomical sites of origin with different natural history and clinical behaviour. Due to these characteristics, it is difficult to accurately predict the efficacy of treatments and the prognosis of patients using conventional clinicopathological criteria. The downstream signaling by FDG accumulation in tumour cells may provide some insight in various tumour lineages with regards to the metabolic alteration.
Given the known natural behaviours of tumours, 18 [F]FDG-PET/CT finding is used as index of increased glucose metabolism and as a marker of tumour viability for which, the degree of FDG uptake presumed to reflect tumour aggressiveness [11] [12] [13] [14] . The upregulation of glucose transporters (Glut-1) has been observed during carcinogenesis in oesophageal, gastric, breast and colon cancers [15] . In patient with head and neck squamous cell carcinoma, FDG is the mainstay of molecular signature to signal the tumour aggressiveness and many studies have focused on the evaluation of small lymph nodes [16] . Upregulated glycolysis, evidenced by increased intratumoural lactate concentrations, is associated with increased incidence of metastasis in cervical and head and neck cancers [17] . In colorectal cancer (CRC), the results indicated that GLUT1 expression is related to intense 18F-FDG uptake [18] .
FDG as a Marker for Tumour Dedifferentiation
In certain tumour cell types, glucose metabolism measured by FDG-PET varies proportionally with the proliferative activity and the grade of malignant cells [19] . Of note, metabolic heterogeneity is common in neuroendocrine tumours, and lesions in the same patient that appear identical on CT often demonstrate quite different MI characteristics. Indirectly, the shift in cellular anabolic metabolism has an indirect signature to the degree in tumour receptor expression. In gastroenteropancreatic neuroendocrine tumour (GEP-NET), indolent tumour may allude benign character for years before dedifferentiation. This tumour harbours somatostatin receptors expression, which generally do not accumulate FDG to a significant degree which indicates that peptide-receptor radionuclide therapy would be unlikely control all sites of disease if used as a single agent (Fig. 2) . They are usually FDGnegative lesions on PET given their inherent low glucose metabolism. Dedifferentiation causes these tumours to grow aggressively and overexpress GLUT1 which is correlated with poor prognosis [20] . This information is crucial for treatment planning because tumour deposits that demonstrate low uptake of somatostatin radiotracers do not respond to radionuclide therapy.
FDG as an Indicator for Tumour Hypoxia
Hypoxic tumours, require increased glycolysis to survive, are usually more invasive than those with normal oxygen levels [21] . This is substantiated by study reports which described an association between hypoxia-related genes and SUV max in patients with lung cancer [22] . In sarcoma, Fig. 1 In-vivo [24] . In this regards, the hypoxic tissue does not accumulate FDG which serves as a vital marker or indicator for poor treatment response utilizing the routine chemotherapy treatment. Therefore, special radiotherapy techniques or targeted therapy that is active in a hypoxic environment offer the potential for improving treatment outcomes for patients with hypoxic cell components within their tumours.
FDG as an Indicator of Cancer Genetic Mutation
Persistent or cyclical hypoxia subsequently exerts selection pressures that lead to constitutive upregulation of glycolysis, even in the presence of oxygen. This constitutive upregulation might occur through mutations or epigenetic changes such as alteration in the methylation patterns of promoter genes. In the era of targeted molecular therapy, tumour response assessment with FDG-PET has already proven invaluable in monitoring the therapeutic effect of treatment such as imatinib on gastrointestinal stromal tumours (GIST). In particular, GISTs, a key molecular driver of these tumours is mutation of the C-KIT oncogene leading to constitutive activation of signaling pathways involved in cell growth, survival and proliferation. Salient features of GIST tumour cells are their expression of the Kit receptor tyrosine kinase and the fact that in a majority of GIST, the Kit receptor harbours an oncogenic mutation.
Kit is a membrane molecule which resides on the surface of cells, carrying a protein kinase that phosphorylates tyrosine residues on substrate proteins [24] . The drug (imatinib) normalises glucose transport into these tumours, and therefore FDG uptake, within days of commencing treatment [25] . The value of FDG uptake in this regards is the return of the glucose of metabolism signal as shown by the FDG accumulation in the tumour cells. In other genetic encoding, several reports suggested that k-ras mutation was associated with poor prognosis and advanced disease [26, 27] . The k-ras is a protein of small GTPase which plays a pivotal role in signal transduction pathway in oncogenesis. In CRC, emerging data strongly suggest that k-ras mutations are predictive of resistance to epidermal growth factor receptor (EGFR) inhibitor treatment in CRCs [28] . Therefore, there may be a correlation between the upregulated GLUT-1, encoding glucose transporter-1 and the tumour inherent FDG concentration. Nevertheless, the CRCs with k-ras mutation positive and mutation negative tumours did not differ significantly in their glycolytic phenotype in this study by Muhammad et al. [28] . It is possible that larger sample sizes could reveal significant differences of the k-ras mutation and its association with tumour FDG-signaling.
FDG as a Predictor of Early Tumour Recurrence
Epigenetic tumour profiling may be important in understanding the downstream signaling of vascular-related tumour growth (VEGF). In this regards, we could explain the relationship of the increased vascular permeability induced in hypoxic environment triggered in tumour proliferation. Hypoxia-inducible factor 1a (HIF-1a) controls oxygen delivery via angiogenesis and metabolic adaptation to hypoxia via glycolysis [29] . In lung cancer, HIF-1a regulates SLC2A1 gene expression in cells that are subjected to hypoxic conditions. The SLC2A1 (also called glucose transporter type 1, GLUT1) gene is the primary Fig. 2 Clonal heterogeneity appears to be a particular feature of NET malignancy. [30] . Therefore, FDG is useful in reflecting epigenetic profiling of tumour which can be exploited early before the genetic remodeling takes place. In addition, correlation of VEGF with altered glycolysis in tumours has been found using mRNA expression in adenocarcinoma of the lung which can be used as predictor for the tumour prognosis [31] . Nevertheless, there is no published data on the direct correlation of FDG with mRNA expression.
FDG as a Predictor of Overall Patient Survival
The complete metabolic response of tumour as imaged on the FDG-PET/CT scan implies a favourable change in tumour apoptosis which is correlated with good prognosis. In a study focusing on invasive ductal breast carcinoma, SUV max on pre-treatment F-18 FDG-PET/CT could be used as a good surrogate marker for the prediction of disease progression [32] . In other study with patient with non-small lung carcinoma, all patients with negative post-therapy FDG-PET scans were alive 2 years after the completion of treatment, whereas 50 % of patients with residual FDG uptake did not survive within that same period [33] . In a study of 90 patients with resectable colorectal carcinoma, survival was longer in patient with low SUV than for patients with a high SUV, with p values of 0.014, 0.025 and 0.00095 for SUVmax cut-off of 5,7 and 10, respectively [11] .
FDG as a Predictor of the Treatment Efficacy
FDG-PET is used to evaluate the tumour response to therapy [34] [35] [36] [37] . The inherent glycolytic metabolism in tumour cells regresses with less viable tumour tissue remains following treatment. In breast cancer, FDG-PET allowed identification of responders to chemotherapy with a high sensitivity and accuracy even after the first and second cycles of therapy [34] . Key drivers in malignant tumour can be explained by the activity of accumulated FDG in tumour tissue. For example key molecule driver in GIST is c-kit gene, FDG-PET scans may be a tool for predicting clinical responses to kinase inhibitors. The PET scan responses in GIST patients whose tumours have c-kit receptor mutations are dramatic and might be explained by a specific effect of c-kit activation on glucose uptake [38] . In a prospective study in 50 patients with diffuse large B cell lymphoma, FDG-PET/CT performed after 2 cycles of chemotherapy showed high negative predictive value FDG-PET which contributes significantly to the improved assessment of treatment response by providing metabolic information that is otherwise unavailable with CT [39] .
Conclusion
FDG is a useful surrogate in-vivo biomarker in the staging, predicting tumour aggressiveness and treatment outcome of different tumour lineage. The results highlighted in this review mainly based on the use of the hybrid imaging employing 18 [F]FDG-PET/CT which offers new data and insight in alluding the downstream signal in tumour biology as correlated with the in-vitro biomarkers. Such correlation between in-vivo and in-vitro tumour profiling facilitates further understanding of the tumour character which plays a pivotal role in ensuring appropriate tumour monitoring and treatment planning. More studies are required in justifying the correlation of FDG and the invitro biomarker as the altered glycolytic metabolic mechanism generally indicates changes in tumour biology.
